Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating etavopivat in adolescents and adults with sickle cell disease to see if it can reduce vaso-occlusive crises painful blockages in blood vessels and protect organs from damage. This phase 3 study will also assess whether etavopivat improves exercise tolerance and reduces fatigue compared to a placebo. The trial is randomized, double-blind, and placebo-controlled to ensure unbiased results on the medications effects. Participants will be randomly assigned to receive either oral etavopivat or a matching placebo. The study treatment is taken by mouth, and participants will be followed closely for about 2 years. This includes monitoring during the treatment period and ongoing assessments to evaluate the drugs impact on sickle cell disease symptoms and related health measures. Throughout the study, participants will undergo evaluations such as blood tests to measure hemoglobin and other markers, 6-minute walking tests to assess exercise capacity, and fatigue questionnaires. Researchers will track the number of vaso-occlusive crises requiring medical contact over 52 weeks as the primary outcome. Safety and efficacy will be monitored regularly, with follow-up continuing until the study ends approximately 4 years after enrollment begins.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of crizanlizumab, a biological drug given at 5 mgkg, compared to a placebo in adolescents and adults aged 12 years and older who have Sickle Cell Disease and experience frequent vaso-occlusive crises VOCs. This phase III, multicenter, randomized, double-blind study includes patients who may or may not be receiving hydroxyurea or hydroxycarbamide therapy. The study aims to better understand how crizanlizumab impacts the rate and severity of VOCs in this population. Participants will be randomly assigned in a 21 ratio to receive either crizanlizumab or placebo, with both groups continuing standard care. The treatment is given as an intravenous infusion and the study allows patients to continue stable doses of hydroxyurea or hydroxycarbamide if they are already on these therapies. The randomization is stratified by hydroxyureahydroxycarbamide use and geographic region. The study treatment period lasts for one year, during which participants receive regular infusions and monitoring. During the trial, participants will be closely monitored with healthcare assessments to track the number of healthcare professional-managed VOCs, time to first VOC, and other important measures such as duration of VOCs, antibody development to the study drug, and changes in hemoglobin levels. Safety is closely evaluated through recording of adverse events over a two-year period. Participants will have regular visits for treatment and evaluation throughout the study, which is expected to last up to six years including follow-up and completion phases.
Actively Recruiting
This research aims to learn about the effectiveness of a task-sharing approach supported by an epilepsy medical records system called BEACON in improving treatment adherence and retention in care for people with epilepsy in western Kenya. Epilepsy is a serious neurological condition with a high burden in this region, and delays or poor adherence to treatment can worsen health outcomes and quality of life. The study compares patients receiving the BEACON intervention to those receiving usual care to assess differences in outcomes such as seizure severity and stigma. Participants are assigned to either the usual care group, where they receive standard epilepsy care from clinicians including consultations and prescriptions, or the BEACON group, where trained clinicians share epilepsy management tasks supported by a medical records system for patient tracking. Reminders about follow-up appointments are given by phone or text, and community health workers help contact participants who miss appointments. Both groups use the same antiseizure medications. During the study, participants will be assessed at baseline, 6, 12, and possibly 18 months. Researchers will collect data on medication adherence through questionnaires and blood levels, retention in care, seizure severity, quality of life, perceived stigma, safety, and mortality. The study also aims to build clinical and research capacity for epilepsy care in the area. Participation involves regular visits and follow-up contacts to support care and monitor progress over time.
Actively Recruiting
This research aims to evaluate two insertable vaginal devices for managing urinary leakage caused by obstetric fistula, a condition that severely impacts quality of life and carries social stigma. The study compares a vaginal cup alone and the cup connected to a leg-attached urine collection bag to increase urine holding capacity. It involves women awaiting fistula surgery or those with unsuccessful surgery, addressing the need for a non-surgical management option in settings with limited access to repair. Participants will use each intervention and a period of leaking freely in a crossover design over four days, with each condition lasting 24 hours, including day and night use. After this short-term phase, participants are re-randomized to use either the cup or the cup device at home for three months. Data collection includes self-reports and clinical checklists to assess device effectiveness, acceptability, and costs. Throughout the study, participants will undergo assessments of urine leakage volume, quality of life, stigma, sleep satisfaction, coping skills, empowerment, safety perception, and device acceptability at multiple time points up to three months. The study also examines material and opportunity costs associated with fistula management. The total observation includes intensive short-term monitoring followed by longer-term home use and follow-up evaluations.
Actively Recruiting
Healthy Volunteer
Researchers are studying adolescent girls and young women aged 15 to 24 years living with HIV who are already on oral antiretroviral therapy ART and have viral suppression. The research includes foundational pharmacokinetic PK and qualitative studies to understand the effects and delivery challenges of long-acting LA injectable cabotegravirrilpivirine compared to standard oral ART, conducted within a large HIV treatment program in Kenya. This study aims to inform a future hybrid effectiveness-implementation trial by evaluating drug interactions and health system readiness. The study involves several components a PK study with five groups to assess drug interactions between LA ART and injectable or implantable contraceptives a qualitative study with participants and stakeholders exploring preferences and system preparedness for co-delivery of LA ART and contraceptives and a 48-week open-label trial randomizing participants to switch to injectable cabotegravirrilpivirine or continue oral ART. Participants also receive contraceptives such as injectable DMPA or hormone implants based on group assignment. Participants are monitored through regular blood sampling every 4 to 12 weeks to measure hormone levels and viral suppression over 48 weeks. Researchers assess adherence and persistence to ART and contraceptive use, as well as implementation outcomes like acceptability and feasibility. Data collected will guide future studies and wider implementation of LA ART and contraceptive co-delivery to improve treatment adherence and reproductive health among young women living with HIV.
Actively Recruiting
Healthy Volunteer
Researchers are developing a pharmacovigilance PV program to monitor adverse pregnancy and infant outcomes, including congenital abnormalities, among HIV-positive and HIV-negative women and their infants at clinical sites linked to the International Epidemiology Databases to Evaluate consortium IeDEA. The study uses a mixed prospective and cross-sectional cohort design to understand possible associations between antiretroviral treatment ART and pregnancy and infant outcomes. The study has three parts Cohort 1 involves prospective recruitment of pregnant women attending antenatal clinics ANC with follow-up including medical record collection and field contact if delivery occurs outside the site. Cohort 2 collects retrospective data from medical records of all deliveries at the site. Cohort 3 focuses on infants with suspected congenital abnormalities CAs, using photos and videos reviewed by experts, with follow-up calls at 1, 6, and 12 months post-delivery to monitor infant health and care engagement. Participants will have pregnancy and infant outcomes assessed at delivery and at 1, 6, and 12 months after birth. Data collection includes medical records, physical exams for congenital abnormalities, and photographic documentation. The study establishes a multiregional PV infrastructure with a Data Coordinating Center at Indiana University to manage and analyze data from Kenya and South Africa. The total study period extends through May 2031, with ongoing participant monitoring and data analysis.
Actively Recruiting
Researchers are evaluating a new approach to help people with uncontrolled hypertension in western Kenya by combining peer-based medication delivery with a Health Information Technology HIT platform. This approach aims to improve medication adherence and lower blood pressure. The study uses the PRECEDE-PROCEED framework to test if this integrated method works better than standard care. The research is led by a multidisciplinary team from NYU Langone Health and focuses on innovative, scalable strategies for global hypertension control. The study compares two groups one receiving door-to-door peer delivery of medications supported by the HIT platform and a control group receiving standard care or standard care with peer medication delivery. The HIT platform offers personalized counseling, teleconsultation among clinicians, peers, and patients, medication refill tracking, and analytics to manage the drug supply chain. The trial is a two-arm cluster randomized controlled implementation research hybrid type 2 trial. Participants will be followed for one year, during which researchers will measure changes in systolic blood pressure, medication adherence using pill counts, and implementation fidelity. Other assessments include blood pressure control, self-reported adherence, and various RE-AIM metrics. Data on patient e-signatures and completed HIT forms will also be collected to monitor engagement. The study starts in November 2025 and continues through April 2028.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether eye-tracking measures can predict autism diagnoses in young children born to mothers with HIV in Kenya. The study focuses on children who were either exposed to HIV but uninfected CHEU or not exposed and uninfected CHUU, aiming to identify neurobehavioral markers linked to autism outcomes. This research builds on the Tabiri study, which compares neurodevelopmental outcomes between these two groups at 24 months of age. The study uses a non-invasive, remote eye-tracking system called Eyelink Portable Duo to collect data on eye movements and pupil diameter while children view pictures and videos. Children aged 24 to 72 months enrolled in the Tabiri study will participate in a one-time eye-tracking session lasting about 15 minutes, during which their eye activity is recorded without any equipment touching the child. The child will sit in a highchair or on a caregivers lap facing a computer screen where visual stimuli are shown. Participants will complete the standard developmental evaluation from the Tabiri study, followed by this eye-tracking activity. Researchers will measure how well the eye-tracking biomarker score agrees with autism diagnoses. The study involves caregivers who speak Kiswahili or English and includes children regardless of HIV status. The entire process is brief and designed to be child-friendly, with outcomes focused on improving early autism detection in this population.
Actively Recruiting
Researchers are conducting a prospective observational study through the African Esophageal Cancer Consortium AfrECC to examine treatment outcomes for adults diagnosed with esophageal cancer. The study aims to describe various treatment methods used, assess patient experiences during and after treatment, and evaluate overall survival rates across participating sites. Participants in this study will receive standard treatments such as chemotherapy, radiation, chemo-radiotherapy, esophageal stenting, surgery, or supportive care as determined by their healthcare providers. The research involves collecting data from medical records and administering questionnaires to capture patient-reported outcomes related to these treatments over up to four years. During the study, participants will complete questionnaires, and their medical charts will be reviewed to gather information on treatment types and patient experiences. Researchers will measure the proportion of participants receiving different treatments, track changes in patient-reported symptom scores over time, and monitor overall survival. The study is planned to continue through June 2027, supporting long-term evaluation of treatment effects and patient quality of life.
Actively Recruiting
This research aims to compare a six-month treatment plan using higher doses of rifampicin, isoniazid, linezolid, and pyrazinamide with the World Health Organizations standard nine-month treatment for tuberculous meningitis TBM in adults and adolescents. Tuberculous meningitis is a serious condition with high risk of death and severe neurological problems. This Phase II, randomized, open-label trial seeks to evaluate if the shorter high-dose regimen can improve functional outcomes compared to the standard care.